. Author manuscript; available in PMC: 2020 Dec 29.

Published in final edited form as: Abdom Radiol (NY). 2019 Feb;44(2):766–774. doi: 10.1007/s00261-018-1752-4

Table 1.

RECIST v1.1 response evaluation categories for target and non-target lesions [7]

Target lesions	Non-target lesions
Complete response (CR)	Complete response (CR)
Disappearance of all target lesions, pathologic lymph nodes must measure short axis < 1 cm	Disappearance of all non-target lesions, all lymph nodes must measure short axis < 1 cm
Partial response (PR)	Non-CR/Non-PD
At least 30% decrease in sum of diameters of target lesions (relative to baseline sum)	Persistence of one or more non-target lesions
Stable disease (SD)	Progressive disease (PD)
Not enough tumor shrinkage to qualify as PR, not enough tumor growth to qualify as progression	Unequivocal progression of existing non-target lesions or any new lesions
Progressive disease (PD)
At least 20% increase in sum of diameters of target lesions (relative to smallest sum), sum must show absolute increase of at least 5 mm, or any new lesions